BACKGROUND: The "Alamo" project is a retrospective analysis of 14,854 patients diagnosed of breast cancer between 1990 and 1997 in 50 Spanish hospitals. METHODS: Alamo I (AI) consisted of 4,532 patients diagnosed with breast cancer between 1990 and 1993. Data were collected in 2000. Alamo II (AII) consisted of 10,322 patients diagnosed between 1994 and 1997. Data were collected in 2003. RESULTS: At presentation, there were (AI vs. AII) 17.6% vs. 24.3% at stage I; 55.5% vs. 53.1% at stage II; 18.7% vs. 15% at stage III; 7.2% vs. 5.9 at stage IV. Median age was 57 (AI) vs. 58 years (AII) and 65.9% vs. 67.2% (AI vs. AII) were post-menopausal. Firstline treatment for disease stages I, II and III was surgery in 91% of patients in both studies. Breast conserving surgery rate increased from 20.2% (AI) to 32.7% (AII). Adjuvant systemic treatments were administered to 87.6% (AI) and 92.8% (AII) of patients. Recurrence rate diminished from 36.6% (AI) to 22.5% (AII) and the 9-year survival rate increased from 63.2% (95% CI: 61.5-64.9) to 70.1% (95% CI: 68.5-71.8). CONCLUSION: Breast cancer outcomes in Spain have improved from 1990-1993 to 1994-1997, likely because of breast cancer screening program implementation and new therapies.
BACKGROUND: The "Alamo" project is a retrospective analysis of 14,854 patients diagnosed of breast cancer between 1990 and 1997 in 50 Spanish hospitals. METHODS:Alamo I (AI) consisted of 4,532 patients diagnosed with breast cancer between 1990 and 1993. Data were collected in 2000. Alamo II (AII) consisted of 10,322 patients diagnosed between 1994 and 1997. Data were collected in 2003. RESULTS: At presentation, there were (AI vs. AII) 17.6% vs. 24.3% at stage I; 55.5% vs. 53.1% at stage II; 18.7% vs. 15% at stage III; 7.2% vs. 5.9 at stage IV. Median age was 57 (AI) vs. 58 years (AII) and 65.9% vs. 67.2% (AI vs. AII) were post-menopausal. Firstline treatment for disease stages I, II and III was surgery in 91% of patients in both studies. Breast conserving surgery rate increased from 20.2% (AI) to 32.7% (AII). Adjuvant systemic treatments were administered to 87.6% (AI) and 92.8% (AII) of patients. Recurrence rate diminished from 36.6% (AI) to 22.5% (AII) and the 9-year survival rate increased from 63.2% (95% CI: 61.5-64.9) to 70.1% (95% CI: 68.5-71.8). CONCLUSION:Breast cancer outcomes in Spain have improved from 1990-1993 to 1994-1997, likely because of breast cancer screening program implementation and new therapies.
Authors: Michelle D Althuis; Jaclyn M Dozier; William F Anderson; Susan S Devesa; Louise A Brinton Journal: Int J Epidemiol Date: 2005-02-28 Impact factor: 7.196
Authors: Miguel Martín; Antonio Llombart-Cussac; Ana Lluch; Emilio Alba; Blanca Munárriz; Ignacio Tusquets; Agustí Barnadas; Anna Balil; Javier Dorta; César Picó Journal: Med Clin (Barc) Date: 2004-01-17 Impact factor: 1.725
Authors: B Fisher; M Bauer; R Margolese; R Poisson; Y Pilch; C Redmond; E Fisher; N Wolmark; M Deutsch; E Montague Journal: N Engl J Med Date: 1985-03-14 Impact factor: 91.245
Authors: Sharon H Giordano; Aman U Buzdar; Terry L Smith; Shu-Wan Kau; Ying Yang; Gabriel N Hortobagyi Journal: Cancer Date: 2004-01-01 Impact factor: 6.860
Authors: M Algara López; X Sanz Latiesas; P Foro Arnalot; M Lacruz Bassols; A Reig Castillejo; J Lozano Galán; I Membrive Conejo; J Quera Jordana; N Rodríguez de Dios Journal: Clin Transl Oncol Date: 2008-01 Impact factor: 3.405
Authors: N Larrañaga; C Sarasqueta; P Martínez-Camblor; M J Mitxelena; A Mendiola; I Martínez-Pueyo; M Basterretxea Journal: Clin Transl Oncol Date: 2009-02 Impact factor: 3.405
Authors: María Concepción Delgado-Sanz; María José García-Mendizábal; Marina Pollán; Maria João Forjaz; Gonzalo López-Abente; Nuria Aragonés; Beatriz Pérez-Gómez Journal: Health Qual Life Outcomes Date: 2011-01-14 Impact factor: 3.186
Authors: Juan Ignacio Arraras; Ana Manterola; Miguel Angel Domínguez; Fernando Arias; Elena Villafranca; Pilar Romero; Enrique Martínez; José Juan Illarramendi; Esteban Salgado Journal: Clin Transl Oncol Date: 2008-08 Impact factor: 3.405
Authors: Iván Márquez-Rodas; Marina Pollán; María José Escudero; Amparo Ruiz; Miguel Martín; Ana Santaballa; Purificación Martínez Del Prado; Norberto Batista; Raquel Andrés; Antonio Antón; Antonio Llombart; Antonio Fernandez Aramburu; Encarnación Adrover; Sonia González; Miguel Angel Seguí; Lourdes Calvo; José Lizón; Álvaro Rodríguez Lescure; Teresa Ramón Y Cajal; Gemma Llort; Carlos Jara; Eva Carrasco; Sara López-Tarruella Journal: PLoS One Date: 2017-10-06 Impact factor: 3.240